Kedudukan dalam Saham
#13758
Evommune, Inc. is a United States-based clinical-stage biotechnology company... Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Perubahan (1 hari)
-2.07%
Perdagangan Evommune, Inc. (EVMN)
Harga EVMN dengan permodalan pasaran b
Modal pasaran bagi Evommune, Inc.(EVMN)
Modal Pasaran: $463.81M
Sehingga August 2026, Evommune, Inc. mempunyai modal pasaran sebanyak $463.81M. Ini menjadikan Evommune, Inc. syarikat ke-13758th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Evommune, Inc. dari 2025 hingga 2026
EVMN berbanding dengan 5 teratas yang paling popular stocks
| Harga EVMN |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.279T
|
+1,138,066.64%
|
|
|
|
|
$4.645T
|
+1,001,354.15%
|
|
|
|
|
$4.067T
|
+876,705.83%
|
|
|
|
|
$3.787T
|
+816,311.07%
|
|
|
|
|
$2.772T
|
+597,507.66%
|
